ViroPharma Incorporated (VPHM)

[surf1944]

8:42AM ViroPharma announces publication of Cinryze Phase 3 trial results in Hereditary Angioedema (VPHM) 13.61 : Co announced that data from Phase 3 studies of Cinryze have been published in New England Journal of Medicine. The paper describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.